Consider participating in the CODY Trial today! CODY: A Study evaluating the safety and efficacy of QTORIN 3.9% Sirolimus Topical Gel for the prevention of Basal Cell Carcinomas (BCCs) in patients with Gorlin Syndrome.   If you are interred in learning more you can click HERE or please contact codytrial@gorlinsyndrome.org.  Any contact made with the pharmaceutical company is not permitted and could impact the integrity of the trial.